

**NOCTURNAL POLYURIA** 

Definition

Role of AVP

Nocturia and nocturnal polyuria

BPH, OAB and nocturnal polyuria


### **NOCTURNAL POLYURIA IS DEFINED AS** THE OVERPRODUCTION OF URINE AT NIGHT<sup>1</sup>

Nocturnal polyuria is present when nocturnal urine volume is:1 >20% of total 24-hour urine volume in patients aged <65 years</li>

- >33% of total 24-hour urine volume in patients aged ≥65 years


Encouraging patients to measure and record the volume of voided urine on a voiding diary can help diagnose nocturnal polyuria<sup>1</sup>


Download the printable voiding diary



### NOCTURNAL POLYURIA IS CAUSED BY A LOW LEVEL OF AVP OR LACK OF SENSITIVITY TO AVP2 Arginine vasopressin (AVP) regulates water and

electrolyte balance in distal tubule and collecting duct. It plays a key role in the control of urine production by increasing the reabsorption of water in the kidneys, thus reducing the volume of urine produced<sup>2</sup>






# CAUSE OF NOCTURIA<sup>2-4</sup>

NOCTURNAL POLYURIA IS THE LEADING



BPH: benign prostatic hyperplasia; BPO: benign prostatic obstruction; NP: nocturnal polyuria; OAB: overactive bladder

\*Global polyuria = urine production >40mL/kg/24 hours





### While nocturia associated with nocturnal polyuria originates at kidney

BPH, OAB AND NOCTURNAL POLYURIA

level due to low levels or lack of sensitivity to AVP, OAB originates at bladder level and BPH originates at prostate level

Nocturnal polyuria is present in the majority of men with BPH





and the majority of women with OAB/LUTS<sup>2,5-8</sup>

have nocturnal polyuria<sup>5,6</sup>

Once upon a time,


nocturia was...

OAB/LUTS reporting nocturia

of the 75% of women with

AVP: arginine vasopressin; BPH: benign prostatic

hyperplasia; OAB: overactive bladder






Kidney

## LEARN MORE

LEARN MORE ABOUT THE IMPACT OF DESMOPRESSIN ON


NOCTURIA DUE TO NOCTURNAL POLYURIA

**MULTIMEDIA** 



## Dr Charlotte Graugaard-Jensen, MD, Ph.D., Department of Urology Aarhus University Hospital, Skejby, Denmark

Todd Cole



### Prof. Dr. Karel Everaert, Department of Urology, Ghent University Hospital, Gent, Belgium

Access more multimedia resources

**SUBMIT** 

YOU CAN CONTACT US DIRECTLY BY EMAIL

CONTACT US

SIGN UP FOR MORE INFORMATION ABOUT NOCDURNA®

todd\_cole@gmail.com

DOWNLOAD THE SUMMARY OF PRODUCT CHARACTERISTICS

## DOWNLOAD SMPC

Email

### REFERENCES van Kerrebroeck P et al. Neurourol Urodyn 2002;21:179-83

This website is intended for healthcare professionals. NOCDURNA is a trademark of Ferring b.V. © 2017 Ferring b.V. All rights reserved.

- Weiss et al. *J Urol* 2011;186:1358-63 Park et al. *Korean J Urol* 2011;54:492-98
- Hofmeester I et al. *J Urol* 2014;191:1028-33 Kurtzman J et al. Curr Opin Urol 2016;26:315-20

Name

- Irwin D et al. *BJU Int* 2008;101:1381-7 Chang S et al. *Urology* 2006;67:541-4 8. Yoong H et al. *Med J Malaysia* 2005;60(3):294-6

- Ferring global Legal disclaimer Contact Us Know Nocturia

